415 related articles for article (PubMed ID: 24630539)
1. Dose-response relationship with clinical outcome for lung stereotactic body radiotherapy (SBRT) delivered via online image guidance.
Kestin L; Grills I; Guckenberger M; Belderbos J; Hope AJ; Werner-Wasik M; Sonke JJ; Bissonnette JP; Xiao Y; Yan D;
Radiother Oncol; 2014 Mar; 110(3):499-504. PubMed ID: 24630539
[TBL] [Abstract][Full Text] [Related]
2. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily online cone-beam computed tomography image-guided radiotherapy.
Grills IS; Hope AJ; Guckenberger M; Kestin LL; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Wilbert J; Xiao Y; Belderbos J
J Thorac Oncol; 2012 Sep; 7(9):1382-93. PubMed ID: 22843086
[TBL] [Abstract][Full Text] [Related]
3. Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy.
Zhao L; Zhou S; Balter P; Shen C; Gomez DR; Welsh JD; Lin SH; Chang JY
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1226-35. PubMed ID: 27209498
[TBL] [Abstract][Full Text] [Related]
4. Assessment of Monte Carlo algorithm for compliance with RTOG 0915 dosimetric criteria in peripheral lung cancer patients treated with stereotactic body radiotherapy.
Pokhrel D; Sood S; Badkul R; Jiang H; McClinton C; Lominska C; Kumar P; Wang F
J Appl Clin Med Phys; 2016 May; 17(3):277-293. PubMed ID: 27167284
[TBL] [Abstract][Full Text] [Related]
5. Defining the optimal planning target volume in image-guided stereotactic radiosurgery of brain metastases: results of a randomized trial.
Kirkpatrick JP; Wang Z; Sampson JH; McSherry F; Herndon JE; Allen KJ; Duffy E; Hoang JK; Chang Z; Yoo DS; Kelsey CR; Yin FF
Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):100-8. PubMed ID: 25442342
[TBL] [Abstract][Full Text] [Related]
6. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
[TBL] [Abstract][Full Text] [Related]
7. A matched-pair analysis of stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer versus early stage non-small cell lung cancer.
Wang X; Zamdborg L; Ye H; Grills IS; Yan D
BMC Cancer; 2018 Oct; 18(1):962. PubMed ID: 30305131
[TBL] [Abstract][Full Text] [Related]
8. Clinical results of mean GTV dose optimized robotic guided SBRT for liver metastases.
Andratschke N; Parys A; Stadtfeld S; Wurster S; Huttenlocher S; Imhoff D; Yildirim M; Rades D; Rödel CM; Dunst J; Hildebrandt G; Blanck O
Radiat Oncol; 2016 May; 11():74. PubMed ID: 27236333
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy of adrenal metastases-A dose-finding study.
Buergy D; Würschmidt F; Gkika E; Hörner-Rieber J; Knippen S; Gerum S; Balermpas P; Henkenberens C; Voglhuber T; Kornhuber C; Barczyk S; Röper B; Rashid A; Blanck O; Wittig A; Herold HU; Brunner TB; Sweeney RA; Kahl KH; Ciernik IF; Ottinger A; Izaguirre V; Putz F; König L; Hoffmann M; Combs SE; Guckenberger M; Boda-Heggemann J
Int J Cancer; 2022 Aug; 151(3):412-421. PubMed ID: 35383919
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.
Davis JN; Medbery C; Sharma S; Pablo J; Kimsey F; Perry D; Muacevic A; Mahadevan A
Radiat Oncol; 2015 May; 10():113. PubMed ID: 25975848
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy for adrenal oligometastasis in lung cancer patients.
Arcidiacono F; Aristei C; Marchionni A; Italiani M; Fulcheri CPL; Saldi S; Casale M; Ingrosso G; Anselmo P; Maranzano E
Br J Radiol; 2020 Nov; 93(1115):20200645. PubMed ID: 32822540
[TBL] [Abstract][Full Text] [Related]
12. The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
Stahl JM; Ross R; Harder EM; Mancini BR; Soulos PR; Finkelstein SE; Shafman TD; Dosoretz AP; Evans SB; Husain ZA; Yu JB; Gross CP; Decker RH
Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1011-1020. PubMed ID: 27869080
[TBL] [Abstract][Full Text] [Related]
13. Breathing-motion-compensated robotic guided stereotactic body radiation therapy : Patterns of failure analysis.
Stera S; Balermpas P; Chan MKH; Huttenlocher S; Wurster S; Keller C; Imhoff D; Rades D; Dunst J; Rödel C; Hildebrandt G; Blanck O
Strahlenther Onkol; 2018 Feb; 194(2):143-155. PubMed ID: 28875297
[TBL] [Abstract][Full Text] [Related]
14. Positron emission tomography for assessing local failure after stereotactic body radiotherapy for non-small-cell lung cancer.
Zhang X; Liu H; Balter P; Allen PK; Komaki R; Pan T; Chuang HH; Chang JY
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1558-65. PubMed ID: 22572078
[TBL] [Abstract][Full Text] [Related]
15. Influence of different treatment techniques and clinical factors over the intrafraction variation on lung stereotactic body radiotherapy.
Rico M; Martínez E; Pellejero S; Bermejo B; Navarrete P; Barrado M; Campo M; Mañeru F; Villafranca E; Aristu J
Clin Transl Oncol; 2016 Oct; 18(10):1011-8. PubMed ID: 26758718
[TBL] [Abstract][Full Text] [Related]
16. Tumor volume change with stereotactic body radiotherapy (SBRT) for early-stage lung cancer: evaluating the potential for adaptive SBRT.
Bhatt AD; El-Ghamry MN; Dunlap NE; Bhatt G; Harkenrider MM; Schuler JC; Zacarias A; Civelek AC; Pan J; Rai SN; Woo SY
Am J Clin Oncol; 2015 Feb; 38(1):41-6. PubMed ID: 24513663
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for local control of stage I non-small cell lung cancer in stereotactic radiotherapy: a retrospective analysis.
Shirata Y; Jingu K; Koto M; Kubozono M; Takeda K; Sugawara T; Kadoya N; Matsushita H
Radiat Oncol; 2012 Oct; 7():182. PubMed ID: 23110967
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic body radiation therapy with higher biologically effective dose is associated with improved survival in stage II non-small cell lung cancer.
Yan SX; Qureshi MM; Dyer M; Truong MT; Mak KS
Lung Cancer; 2019 May; 131():147-153. PubMed ID: 31027693
[TBL] [Abstract][Full Text] [Related]
19. The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.
Shaverdian N; Tenn S; Veruttipong D; Wang J; Hegde J; Lee C; Cao M; Agazaryan N; Steinberg M; Kupelian P; Lee P
Br J Radiol; 2016; 89(1059):20150963. PubMed ID: 26764282
[TBL] [Abstract][Full Text] [Related]
20. Lack of a dose-effect relationship for pulmonary function changes after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Guckenberger M; Klement RJ; Kestin LL; Hope AJ; Belderbos J; Werner-Wasik M; Yan D; Sonke JJ; Bissonnette JP; Xiao Y; Grills IS
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1074-81. PubMed ID: 23154077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
